SAMSUNG-SEMICONDUCTOR
15.9.2020 11:02:12 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced four new Samsung ISOCELL image sensors for its 0.7 micrometer (μm)-pixel product lineup; 108-megapixel (Mp) ISOCELL HM2, 64Mp ISOCELL GW3, 48Mp ISOCELL GM5 and 32Mp ISOCELL JD1. With the new 0.7μm ISOCELL technology, Samsung plans to expand the ultra-high-resolution offerings to mainstream smartphones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005521/en/
“Samsung continues to pioneer innovations, such as ISOCELL Plus and Smart ISO, to deliver more pixels in a smaller package,” said Yongin Park, executive vice president of the sensor business at Samsung Electronics. “Last year, Samsung introduced the industry’s first 0.7μm-pixel image sensor and the first 108Mp sensors. Now we are bringing more of the advanced pixel technologies to mobile cameras in a variety of options that will enable high-resolution images and sleeker designs in a wider selection of tomorrow’s mobile devices.”
For ultra-high-resolution image sensors, even a mere 0.1μm-difference per pixel can have a significant impact on the overall size of the sensor as well as the height of the camera module. With pixels at 0.7μm, Samsung’s newest image sensors are up to 15-percent smaller than the 0.8μm sensors of the same resolution and reduce the height of the camera module by up to 10 percent. Smaller form factors give smartphone manufacturers more flexibility, such as added features or more streamlined designs, when developing their next-generation devices.
To collect an ample amount of light and increase the full well capacity despite the minute pixel sizes, Samsung has incorporated its advanced ISOCELL Plus and Smart-ISO technologies, especially optimized for 0.7μm. ISOCELL Plus retains the received light with a wall-like structure around the pixel while Smart-ISO makes full use of the incoming light by intelligently adjusting the ISO accordingly for optimal exposure.
In the latest 0.7μm products to be introduced later this year, Samsung will start rolling out an enhanced pixel technology, ISOCELL 2.0, which allows excellent performance despite the challenges with decreasing pixel sizes. The new technology further enhanced the wall structure between cells, resulting in added light sensitivity of up to 12 percent compared to the current ISOCELL Plus technology.
The New 0.7μm Lineup;
- ISOCELL HM2 is Samsung’s third 108Mp image sensor following the HMX and HM1. The new 108Mp-sensor is around 15-percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent. The HM2 features Super PD, a faster and more effective phase detecting auto focus solution, and like the HM1, comes with a nine-pixel binning technology as well as 3x lossless zoom.
- ISOCELL GW3 is a 64Mp-image sensor optimized for mainstream devices. Thanks to the smaller pixel size, the GW3’s optical size is nearly identical to that of Samsung’s 0.8μm 48Mp image sensor. In addition to Tetracell and Smart-ISO technologies that help the sensor take bright images with high color fidelity, the GW3 is ideal for active lifestyles, featuring gyro-based electronic image stabilization (EIS) for sharper still photos and steadier videos. The image sensor supports video recording at up to 4K resolution at 60 frames-per-second (fps).
- ISOCELL GM5 is a versatile 48Mp-image sensor designed for use in telescoping or ultra-wide angle cameras. When used as a 5x optical telescoping sensor for folded-zoom, the GM5 takes full advantage of the compact 0.7μm pixel size that minimizes the camera bulge. For ultra-wide shots, the GM5 supports high-speed full-HD recording at 480fps. The sensor also offers a staggered-HDR feature, a faster and more power-efficient HDR technology that expedites image processing by sending a readout of long, medium, and short exposures of each row of pixels respectively to the mobile processor. As the readout is performed based on Tetracell’s 1.4μm two-by-two pixels, rather than at the individual 0.7μm-pixel level, staggered-HDR can provide brighter and clearer images with less noise.
- ISOCELL JD1 is the industry’s smallest 32Mp-image sensor at 1/3.14-inches, making it an ideal solution for smartphones with bezel-less displays that incorporate a hole-in-active-area or motorized pop-up mechanism for the front-facing camera. Even with 32-million pixels to capture a highly detailed selfie, the camera sits comfortably under the display as the height of the sensor’s camera module is comparable to those of 0.9μm 20Mp or 1.0μm 16Mp sensors. Like the GM5, the JD1 is also the one the first ISOCELL image sensors to offer staggered-HDR.
Samsung ISOCELL HM2, GW3 and JD1 are currently in mass production, and the company is sampling GM5.
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005521/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
